1. Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. (3rd May 2016) Authors: De Masson, A.; Giustiniani, J.; Marie-Cardine, A.; Bouaziz, J. D.; Dulphy, N.; Gossot, D.; Validire, P.; Tazi, A.; Garbar, C.; Bagot, M.; Merrouche, Y.; Bensussan, A. Journal: Oncoimmunology Issue: Volume 5:Number 5(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large‐cell lymphoma1111. (1st August 2016) Authors: Battistella, M.; Janin, A.; Jean‐Louis, F.; Collomb, C.; Leboeuf, C.; Sicard, H.; Bonnafous, C.; Dujardin, A.; Ram‐Wolff, C.; Kadin, M.E.; Bensussan, A.; Bagot, M.; Michel, L. Journal: British journal of dermatology Issue: Volume 175:Number 2(2016) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large‐cell lymphoma4. (13th July 2016) Authors: Battistella, M.; Janin, A.; Jean‐Louis, F.; Collomb, C.; Leboeuf, C.; Sicard, H.; Bonnafous, C.; Dujardin, A.; Ram‐Wolff, C.; Kadin, M.E.; Bensussan, A.; Bagot, M.; Michel, L. Journal: British journal of dermatology Issue: Volume 175:Number 2(2016) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. KIR3DL2 expression in patients with adult T‐cell lymphoma/leukaemia. (1st July 2018) Authors: Hurabielle, C.; Leboeuf, C.; Ram‐Wolff, C.; Meignin, V.; Rivet, J.; Vignon‐Pennamen, M.‐D.; Bonnafous, C.; Sicard, H.; Fite, C.; Raffoux, E.; Arnulf, B.; Oksenhendler, E.; Sicre de Fontbrune, F.; Peffault de Latour, R.; Socié, G.; Bouaziz, J.‐D.; Lebbé, C.; Bensussan, A.; Janin, A.; Bagot, M. Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. KIR3DL2 expression in patients with adult T‐cell lymphoma/leukaemia. (9th May 2018) Authors: Hurabielle, C.; Leboeuf, C.; Ram‐Wolff, C.; Meignin, V.; Rivet, J.; Vignon‐Pennamen, M.‐D.; Bonnafous, C.; Sicard, H.; Fite, C.; Raffoux, E.; Arnulf, B.; Oksenhendler, E.; Sicre de Fontbrune, F.; Peffault de Latour, R.; Socié, G.; Bouaziz, J.‐D.; Lebbé, C.; Bensussan, A.; Janin, A.; Bagot, M. Journal: British journal of dermatology Issue: Volume 179:Number 1(2018) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long‐term efficacy and safety of alemtuzumab in advanced primary cutaneous T‐cell lymphomas. (1st March 2014) Authors: de Masson, A.; Guitera, P.; Brice, P.; Moulonguet, I.; Mouly, F.; Bouaziz, J.‐D.; Battistella, M.; Madelaine, I.; Roux, J.; Ram‐Wolff, C.; Cayuela, J.‐M.; Bachelez, H.; Bensussan, A.; Michel, L.; Bagot, M. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long‐term efficacy and safety of alemtuzumab in advanced primary cutaneous T‐cell lymphomas. (March 2014) Authors: de, A.; Guitera, P.; Brice, P.; Moulonguet, I.; Mouly, F.; Bouaziz, J.‐D.; Battistella, M.; Madelaine, I.; Roux, J.; Ram‐Wolff, C.; Cayuela, J.‐M.; Bachelez, H.; Bensussan, A.; Michel, L.; Bagot, M. Journal: British journal of dermatology Issue: Volume 170:Number 3(2014:Mar.) Page Start: 720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results. (June 2017) Authors: Bagot, M.; Porcu, P.; Ram‐Wolff, C.; Khodadoust, M.; Basem, W.; Battistella, M.; Marie‐Cardine, A.; Vermeer, M.; Mathieu, S.; Whittaker, S.; Duvic, M.; Bensussan, A.; Paturel, C.; Bonnafous, C.; Thonnart, N.; Widemann, A.; Bonin, C.; Sicard, H.; Paiva, C.; Pilz, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. (1st June 2020) Authors: Roelens, M.; de Masson, A.; Ram‐Wolff, C.; Maki, G.; Cayuela, J‐M.; Marie‐Cardine, A.; Bensussan, A.; Toubert, A.; Bagot, M.; Moins‐Teisserenc, H. Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. (22nd October 2019) Authors: Roelens, M.; de Masson, A.; Ram‐Wolff, C.; Maki, G.; Cayuela, J‐M.; Marie‐Cardine, A.; Bensussan, A.; Toubert, A.; Bagot, M.; Moins‐Teisserenc, H. Journal: British journal of dermatology Issue: Volume 182:Number 6(2020) Page Start: 1415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗